EMA Authorised: Gilenya (fingolimod hydrochloride) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency authorised Gilenya (fingolimod hydrochloride) for the treatment of multiple sclerosis, with Novartis Europharm Limited as the mark…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis. MAH: Novartis Europharm Limited. Decision date: 02/02/2026